New Analysis Estimates Numbers of Older U.S. Adults Who May Benefit From Statin Therapy
American Heart Association rapid access journal report:
- A new analysis estimates more than 11 million older Americans could be newly eligible for statin therapy if findings from the JUPITER trial are adopted into guidelines.
- That could take the number of older adults eligible for statin therapy to over 44 million, or 80 percent of that population.
- The analysis highlights a public health challenge since, even under current treatment guidelines, fewer than half of older Americans who qualify for statin therapy actually get it.
- More analysis of the JUPITER data will be needed before findings are put into practice.
Using data from the 1999-2004 National Health and Nutrition Examination Survey, researchers found that 33.5 million older Americans (men age 50 years and older and women age 60 years and older) are currently taking a statin (24.4 percent) or have risks that would indicate a need for statin therapy based on current guidelines but do not take a statin (33.5 percent).
They estimated that an additional 19.2 percent of older adults could be considered eligible for statin therapy based on their matching the inclusion criteria used in a recently published clinical trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), presented in November at the American Heart Association’s Scientific Sessions 2008 in
“Based on our analysis, more than 44.7 million older Americans might have an indication for statin therapy when you consider those who already meet current guidelines for statin therapy and those who might be eligible based on the criteria proposed in JUPITER,” said the study’s lead author
The study is a numerical analysis rather than an endorsement of using statins to aggressively lower cholesterol and high sensitivity C-reactive protein (hsCRP) in people not currently considered candidates for that therapy, as was done in JUPITER. Additionally, the exclusion criteria for study participants in the JUPITER trial may make it difficult to generalize those findings.
“Certainly the JUPITER findings were intriguing and they will be evaluated as any future revisions are considered for treatment guidelines for reducing cardiovascular risk,” said American Heart Association president
Spatz, who was not involved in the JUPITER trial, said her analysis does highlight an important challenge for healthcare providers and systems: Even under current treatment guidelines, fewer than half (42 percent) of older Americans who qualify for statin therapy actually get it. Although there are many possible reasons for this lack of treatment, many patients who could benefit are being missed — and this problem is likely to increase if the size of the population eligible for statins increases, she said.
“We must reduce risk, both with lifestyle changes and when indicated, with medications,” said Gardner. “Clearly, as a nation, we are not adequately reducing the risk of those who, even under current guidelines, already need statin treatment but are not receiving it. Determining the most effective ways to do that is paramount.”
In JUPITER, researchers explored whether statin use reduced heart attacks, strokes and death in patients who did not have cholesterol levels that would dictate cholesterol-lowering treatment, but had elevated levels of hsCRP, an inflammatory marker. Elevated levels of hsCRP have been associated with the development of coronary artery disease.
“That trial was terminated early after an interim analysis showed greater benefits in people taking statins than in those taking a placebo,” Spatz said. “Our suspicion was that the findings from JUPITER might potentially impact a sizeable number of older adults in
Spatz used information from the 1999-2004 National Health and Nutrition Examination Survey (NHANES), a periodic survey conducted by the federal government that is statistically representative of the U.S. population. Her study examined data from a subset of 2,322 older men and women who answered the NHANES survey questionnaires and also allowed researchers to take a fasting blood sample to test for a variety of cardiovascular risk factors, including cholesterol level and level of hsCRP.
Using those data, Spatz and her co-authors estimate that another 13.9 percent (8 million) of the older population would be candidates for statin therapy under the strictest JUPITER trial criteria — hsCRP at or above 2 milligrams per liter (mg/L) and low-density lipoprotein cholesterol (LDL) under 130 milligrams per deciliter (mg/dL), Spatz said.
She estimated that another 3 million people, or 5.3 percent of the older population, would qualify for statins under an expanded, but still plausible, treatment criteria of hsCRP at or above 2 mg/L and LDL cholesterol between 130 and 160 mg/dL.
Overall, the people who may now qualify for a statin based on JUPITER’s findings share many characteristics with those who already qualify for a statin medication. The two groups were similar in age, race and socioeconomic status and had equal degrees of high blood pressure and abdominal obesity, both of which are risk factors for heart disease. Compared to people who have no indication for a statin medication, the JUPITER group was distinguishable in that they were more likely to be female and older, and to have obesity, high blood pressure and the metabolic syndrome.
“This further suggests we may be missing a group of people who in addition to having an elevated hsCRP, have other features that put them at risk for heart disease, and for whom a statin medication may be beneficial,” Spatz said.
Spatz hopes her study will help provide important information for the development of future guidelines about using statin medications to reduce cardiovascular disease by providing some of the information necessary to determine whether the number of people who would get statin therapy under JUPITER criteria would be cost-effective from a public health standpoint.
Dr. Spatz’s research is funded through the Robert Wood Johnson Clinical Scholars Program.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
SOURCE American Heart Association